<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to explore the clinical effect and complications of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> through retrospective analysis of 75 patients (42 male, 33 female; aged from 13 to 72 years old) received allo-PBSCT from HLA matched (n=61) or haploidentical donors (n=14) </plain></SENT>
<SENT sid="1" pm="."><plain>75 patients included 35 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 30 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, 5 patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 3 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, one patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and one patients with <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Conditioning regimens were (1) Cy/TBI or Bu/Cy; (2) Cy/TBI+Ara-C; (3) fludarabine+TBI/or (<z:chebi fb="3" ids="3498">CTX</z:chebi>+ATG) </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">Minimal residual disease</z:e> has been monitored regularly by PCR and FISH </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> or ATG and anti-CD25 monoclonal antibody and <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>Relapsing patients after transplantation received DLI and/or chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Patient with <z:mp ids='MP_0005481'>CML</z:mp> were treated with <z:chebi fb="0" ids="45783">imatinib</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The results showed that 74 patients had hematopoietic reconstitution, and eventually converted to full donor chimerism by FISH or PCR-STR </plain></SENT>
<SENT sid="8" pm="."><plain>The median time for the initial hematopoietic reconstitution was 15 (5-25) days </plain></SENT>
<SENT sid="9" pm="."><plain>46 out of 75 patients were alive and median duration was 23 (2-61) months </plain></SENT>
<SENT sid="10" pm="."><plain>Among 29 dead patients, 9 died of disease relapse, 7 died of III-IV grade of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and 7 died of severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (2 patients developed interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain>9 out of 14 patients received haploidentical transplantation were alive, and the time of event-free survival was 30 (6-53) months, the mean survival time of 5 died patients was 7 (2-17) months </plain></SENT>
<SENT sid="12" pm="."><plain>16 patients were infected by cytomegalovirus, 2 of them died of interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>None of them suffered from <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> in the liver </plain></SENT>
<SENT sid="14" pm="."><plain>It is concluded that allo-PBSCT is effective to treat refractory <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e>, and DLI/or chemotherapy should be used in the patients relapsing after transplantation </plain></SENT>
</text></document>